Best Review Paper Award

Paola Di Carlo
University of Palermo, Italy

Paola Di Carlo is an Italian researcher affiliated with the University of Palermo whose scientific work spans microbiology, infectious diseases, microbiome research, nanomedicine, antimicrobial resistance, and translational medicine. Through a substantial publication record and multidisciplinary collaborations, she has contributed to the advancement of knowledge concerning microbial ecology, cancer-related microbiota, respiratory infections, and innovative therapeutic strategies. Her scholarly profile demonstrates sustained engagement with emerging topics in medicine and health sciences, making her a notable candidate for recognition through the Best Review Paper Award within the International Environmental Scientists Award program.[1]

Abstract

This article reviews the academic profile, publication achievements, and scientific contributions of Paola Di Carlo. Her research portfolio reflects a strong commitment to understanding microbiological processes involved in human disease, including microbiome dysbiosis, antimicrobial resistance, respiratory pathogens, and cancer-associated microbial ecosystems. Recent publications emphasize review-based synthesis of emerging evidence and provide clinically relevant perspectives for researchers and healthcare professionals.[2]

Keywords

Microbiome Research, Antimicrobial Resistance, Infectious Diseases, Nanomedicine, Biliary Cancer, Translational Medicine, Clinical Microbiology, Review Articles, Medical Sciences, Evidence Synthesis.

Introduction

Modern biomedical research increasingly relies on interdisciplinary approaches that integrate microbiology, clinical medicine, molecular biology, and public health. Within this landscape, Paola Di Carlo has developed a research portfolio characterized by scientific rigor and relevance to contemporary healthcare challenges. Her publications explore the relationship between microbial communities and disease progression, while also assessing therapeutic innovations and preventive strategies.[3]

Research Profile

With 147 indexed publications, 2,368 citations, and an h-index of 25, Di Carlo has established a substantial scholarly presence within medicine and health sciences. Her work frequently addresses microbiological determinants of disease, antimicrobial stewardship, pathogen surveillance, and microbiome-mediated mechanisms. The breadth of her research demonstrates both clinical relevance and translational value across multiple healthcare domains.[1]

Research Contributions

• Investigation of microbiome dysbiosis and its implications for cancer development and therapeutic interventions.
• Research on multidrug-resistant pathogens and innovative antimicrobial approaches.
• Evaluation of lipid nanoparticle systems to enhance antibiofilm activity and drug delivery.
• Clinical studies involving Legionella pneumophila infections and epidemiological assessment.
• Comprehensive review articles synthesizing current evidence on biliary and pancreatic tract diseases.

Publications

• Polyphenols and ADPKD: A Further Aid from Nature? Life (2026).
• Biliary Tract and Pancreatic Cancer (BTPC) in Adult Patients: The Role of the Biliary Microbiota in Cancer and Therapeutic Strategies—A Scoping Review. Cancers (2026).
• Multicomponent Lipid Nanoparticles as a Tool to Potentially Improve the Antibiofilm Activity of Resveratrol against MDR Clinical Isolates. ACS Omega (2026).
• Microbiome Dysbiosis, Chemoprophylaxis, and Tumor Microenvironment in Biliary–Pancreatic Tract Diseases.
• Community-Acquired Legionella pneumophila Pneumonia: A Case-Control Study in Adult Inpatients from 2019 to 2024. Pathogens (2025).

Research Impact

The impact of Di Carlo’s research is reflected through consistent citation activity, interdisciplinary collaborations, and publication in internationally recognized journals. Her review articles provide valuable syntheses of emerging evidence, enabling clinicians and researchers to better understand disease mechanisms and potential treatment pathways. Such contributions support evidence-based healthcare decision-making and stimulate future research initiatives.[4]

Award Suitability

Paola Di Carlo demonstrates qualities commonly associated with recipients of review-focused academic distinctions. Her ability to consolidate complex scientific evidence, identify knowledge gaps, and communicate research findings in accessible scholarly formats contributes significantly to the advancement of medicine and health sciences. The depth and relevance of her recent review publications align strongly with the objectives of the Best Review Paper Award.[5]

Conclusion

Paola Di Carlo has developed a distinguished academic record characterized by productive scholarship, interdisciplinary engagement, and meaningful contributions to microbiology and medical research. Her publication portfolio, citation impact, and emphasis on comprehensive review-based scholarship provide a strong foundation for recognition within international scientific award programs. The available evidence supports her suitability for acknowledgment through the Best Review Paper Award.

External Links

• ORCID Profile
• Scopus Author Profile
• Google Scholar Profile
• Award Website

References

1. Elsevier. (n.d.). Scopus author details: Paola Di Carlo, Author ID 6604018676. Scopus.
   https://www.scopus.com/authid/detail.uri?authorId=6604018676
2. Di Carlo, P. et al. (2026). Polyphenols and ADPKD: A Further Aid from Nature? Life.
   https://doi.org/10.3390/life16061022
3. Di Carlo, P. et al. (2026). Biliary Tract and Pancreatic Cancer in Adult Patients: A Scoping Review. Cancers.
   https://doi.org/10.3390/cancers18121875
4. Di Carlo, P. et al. (2026). Multicomponent Lipid Nanoparticles and Antibiofilm Activity. ACS Omega.
   https://doi.org/10.1021/acsomega.5c12649
5. Di Carlo, P. (2026). Microbiome Dysbiosis, Chemoprophylaxis, and Tumor Microenvironment in Biliary–Pancreatic Tract Diseases. OSF.
   https://doi.org/10.17605/osf.io/uc34p
6. Di Carlo, P. et al. (2025). Community-Acquired Legionella pneumophila Pneumonia: A Case-Control Study in Adult Inpatients from 2019 to 2024. Pathogens.
   https://doi.org/10.3390/pathogens15010013